Related Experiment Video
Updated: Aug 16, 2026

10:03
Screening for Amyloid Aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis
Published on: July 16, 2008
Zelmac (Novartis AG)
1Norman Consulting, 18 Pink Lane, Burnham, Buckinghamshire, SL1 8JW, UK. pn29@student.open.ac.uk
Abstract:
Novartis is developing Zelmac (SDZ-HTF-919), a 5-HT4 receptor partial agonist, which is in phase III clinical trials for the treatment of gastric motility disorders and irritable bowel syndrome (IBS). Warburg Dillon Read estimated (in January 1999) that Zelmac will achieve sales of 240 million Swiss Francs in 2001.
